Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 32 | ECE2013 | Next issue

15th European Congress of Endocrinology

Symposia

Clinical care of the pheochromocytoma patient

ea0032s14.1 | Clinical care of the pheochromocytoma patient | ECE2013

Clinical care of the pheochromocytoma patient

Timmers Henri

Paragangliomas (PGLs) derive from either sympathetic tissue in adrenal and extra-adrenal locations, or from parasympathetic tissue of the head and neck. Adrenal PGLs are usually referred to as pheochromocytomas. Most patients with adrenal and extra-adrenal abdominal PGLs have increased plasma and urine concentrations of catecholamines (dopamine, norepinephrine and epinephrine). Typical symptoms and signs of catecholamine excess include headache, palpitations, diaphoresis, and ...

ea0032s14.2 | Clinical care of the pheochromocytoma patient | ECE2013

Pheochromocytoma imaging

Pacak Karel

Pheochromocytomas (PHEO) and paragangliomas (PGL) are neuroendocrine tumors that were born to be imaged using specific radiopharmaceuticals. This is based on the expression of the cell membrane norepinephrine transporter system and somatostatin receptors, as well as GLUT and amino acid transporters found on PHEO/PGL cells.Anatomical imaging modalities (e.g. CT or MRI) may define the size, shape, structure and enhancement of tumors well, but they lack the...

ea0032s14.3 | Clinical care of the pheochromocytoma patient | ECE2013

Treatment of malignant pheochromocytomas and paragangliomas

Baudin E

Pheochromocytomas and paragangliomas are rare neuroendocrine chromaffine tumors located in the adrenal or extra-adrenal sites, respectively. Malignant pheochromocytomas or paragangliomas represent 10–20% (MPP) of these patients and are defined by the presence or occurrence of metastasis, in non chromaffin organs. MPP are characterized by their heterogeneous presentation as testified by their variety in primary locations, levels and type of hormone secretions, percentage o...